{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T01:50:26Z","timestamp":1693878626606},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,17]],"date-time":"2015-07-17T00:00:00Z","timestamp":1437091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Brasileira de Hematologia e Hemoterapia"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.bjhh.2015.07.004","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T21:27:51Z","timestamp":1438205271000},"page":"341-347","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase"],"prefix":"10.1016","volume":"37","author":[{"given":"Vanessa Fiorini","family":"Furtado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo Rengel","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise Siqueira","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Vin\u00edcius","family":"Staziaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaneuza Ara\u00fajo Moreira","family":"Funke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bjhh.2015.07.004_bib0130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.bjhh.2015.07.004_bib0135","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bjhh.2015.07.004_bib0140","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.bjhh.2015.07.004_bib0145","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bjhh.2015.07.004_bib0150","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bjhh.2015.07.004_bib0155","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/cncr.21756","article-title":"Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal","volume":"106","author":"Cortes","year":"2006","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bjhh.2015.07.004_bib0160","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3324\/haematol.13529","article-title":"The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600mg: the GIMEMA CML Working Party experience after a 7-year follow-up","volume":"94","author":"Palandri","year":"2009","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.bjhh.2015.07.004_bib0165","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bjhh.2015.07.004_bib0170","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.bjhh.2015.07.004_bib0175","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"8378","key":"10.1016\/j.bjhh.2015.07.004_bib0180","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(84)92179-2","article-title":"Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia","volume":"1","author":"Speck","year":"1984","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.bjhh.2015.07.004_bib0185","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bjhh.2015.07.004_bib0190","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bjhh.2015.07.004_bib0255","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bjhh.2015.07.004_bib0195","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.21032","article-title":"Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia \u2013 comparison with historic experience","volume":"103","author":"Kantarjian","year":"2005","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.bjhh.2015.07.004_bib0200","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","article-title":"Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase","volume":"117","author":"Jiang","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bjhh.2015.07.004_bib0205","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1590\/S1516-84842005000300005","article-title":"Therapy of chronic myeloid leukemia with imatinib mesylate in Brazil: a study of 98 cases","volume":"27","author":"Funke","year":"2005","journal-title":"Rev Bras Hematol Hemoter"},{"issue":"1","key":"10.1016\/j.bjhh.2015.07.004_bib0210","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.11863","article-title":"The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase","volume":"100","author":"Sneed","year":"2004","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.bjhh.2015.07.004_bib0215","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/leu.2013.171","article-title":"The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib","volume":"27","author":"Hoffmann","year":"2013","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.bjhh.2015.07.004_bib0260","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bjhh.2015.07.004_bib0225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12288-010-0048-9","article-title":"Total leukocyte counts and the requirement of dose reduction due to cytopenias as prognostic indicators affecting response to imatinib in chronic myeloid leukemia","volume":"27","author":"Tripathi","year":"2011","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"10","key":"10.1016\/j.bjhh.2015.07.004_bib0230","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bjhh.2015.07.004_bib0235","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2003-02-0371","article-title":"Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate","volume":"103","author":"O\u2019Dwyer","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bjhh.2015.07.004_bib0240","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3324\/haematol.13045","article-title":"Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level","volume":"93","author":"Brenner","year":"2008","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.bjhh.2015.07.004_bib0245","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s10552-009-9417-9","article-title":"Trends in adult leukemia incidence and survival in Denmark, 1943\u20132003","volume":"20","author":"Thygesen","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"6","key":"10.1016\/j.bjhh.2015.07.004_bib0250","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/cncr.11629","article-title":"Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"98","author":"Cortes","year":"2003","journal-title":"Cancer"}],"container-title":["Revista Brasileira de Hematologia e Hemoterapia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1516848415001103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1516848415001103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T11:26:23Z","timestamp":1537442783000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1516848415001103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S1516848415001103"],"URL":"https:\/\/doi.org\/10.1016\/j.bjhh.2015.07.004","relation":{},"ISSN":["1516-8484"],"issn-type":[{"value":"1516-8484","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accelerated phase chronic myeloid leukemia: evaluation of clinical criteria as predictors of survival, major cytogenetic response and progression to blast phase","name":"articletitle","label":"Article Title"},{"value":"Revista Brasileira de Hematologia e Hemoterapia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjhh.2015.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}